AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: AZD4604 for inhalation via DPIDrug: AZD4604 for oral administrationDrug: AZD4604 for IV administrationDrug: Placebo for AZD4604 for inhalation via DPI
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT04769869
- Locations
- π¬π§
Research Site, Manchester, United Kingdom
Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Painful Osteoarthritis of the Knee
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT04770428
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
Phase 1
Completed
- Conditions
- Bioequivalence
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT04768985
- Locations
- πΊπΈ
Research Site, Salt Lake City, Utah, United States
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Phase 3
Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT04765059
- Locations
- πͺπΈ
Research Site, Valencia, Spain
Anifrolumab Early Access Program
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04750057
ALICIA (Acalabrutinib in CLL Therapy)
Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT04746950
- Locations
- π·πΊ
Research Site, Saratov, Saratov Region, Russian Federation
Study of AZD2811 + Durvalumab in ES-SCLC
Phase 2
Active, not recruiting
- Conditions
- Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT04745689
- Locations
- πͺπΈ
Research Site, Valencia, Spain
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 601
- Registration Number
- NCT04742192
- Locations
- π»π³
Research Site, Ho Chi Minh, Vietnam
Capivasertib China PK Study
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04742036
- Locations
- π¨π³
Research Site, Shanghai, China
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 506
- Registration Number
- NCT04739761
- Locations
- π¬π§
Research Site, Edinburgh, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath